**FOI Ref: 6463**

**Category(ies): Clinical - Drugs**

**Subject: Antifungal Treatment**

**Date Received: 27/06/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I would be grateful if you would please answer the following questions concerning antifungal treatment within your organisation. | |
| 1. What is the number of patients in the last 12 months treated with the following product lines? 2. anidulafungin 3. caspofungin 4. micafungin | a. 51  b. 17  c. 0 |
| 1. What is the split of indication over the last 12 months for the following product lines? 2. anidulafungin 3. caspofungin 4. micafungin | * 17 Candida, * 12 fungal suspected/empirical, * 4 microbiology recommended, * 2 intra-abdominal sepis, * 1 small bowel leak, * 1 pneumomediastinium, * 6 yeast in blood culture, * 1 oesophageal perforation, * 3 sepsis, * 2 perforation, * 1 upper GI perforation, * 1 yeast in nephrostomy tube, * 1 pancreatic collection * 2 fungal cover for chest, * 5 fungal infection, * 1 aspergillosis, * 1 chemo antifungal prophylaxis, * 1 aml refractory fever, * 2 neutropenic sepsis, * 1 MDS, * 2 candida, * 1 aml prophylaxis, * 1 aml chest sepsis, * 1 copious oral secretions, * 1 oesophageal perf  1. Don’t do |
| 1. For each of the indication splits of the 3 product lines mentioned previously (anidulafungin, caspofungin and micafungin from Q2) list the average length of treatment time. | Anidulafungin = 8.5 days  Caspofungin = 8.6 days  Micafungin = 0 |